<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145235</url>
  </required_header>
  <id_info>
    <org_study_id>31GB0905</org_study_id>
    <nct_id>NCT01145235</nct_id>
  </id_info>
  <brief_title>Swedish Macrolane Registry</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <brief_summary>
    <textblock>
      A Registry to monitor long term safety in female subjects after treatment with Macrolane
      VRF20 and/or MacrolaneT VRF30 in the breasts.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To document the incidence of breast cancer in female subjects after treatment with Macrolane VRFs in the breasts when the product is used in clinical practice.</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Breast Augmentation</condition>
  <arm_group>
    <arm_group_label>Females previously treated with Macrolane in their breasts.</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All clinics treating females with Macrolane in the breast will be asked to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females previously treated with Macrolane VRF in the breasts

          2. Females continuously being treated with Macrolane VRF in the breasts, initial
             treatment or re-treatment.

        Exclusion Criteria:

        No exclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frida Nyberg, MSc</last_name>
    <email>Frida.nyberg@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr Per Hedén</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Hedén, MD, PhD</last_name>
      <email>per.heden@ak.se</email>
    </contact>
    <investigator>
      <last_name>Per Hedén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 25, 2016</lastchanged_date>
  <firstreceived_date>June 15, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast augmentation with Macrolane</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
